Glaxosmithkline Pharmaceuticals Ltd

Glaxosmi. Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Glaxosmithkline Pharmaceuticals Ltd

₹ 3,299 1.08%
30 May - close price
gsk-india.com BSE: 500660 NSE: GLAXO
About

GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)

Key Points

Leading Global Health care company[1] GlaxoSmithKline Pharmaceutical is a part of GlaxoSmithKline plc (GSK), a British multinational pharmaceutical company headquartered in London. GSK underwent a merger in 2000 of Glaxo Wellcome and SmithKline Beecham, and is the world’s sixth-largest pharmaceutical company.

Website BSE NSE
  • Market Cap ₹ 55,880 Cr.
  • Current Price ₹ 3,299
  • High / Low ₹ 3,398 / 1,921
  • Stock P/E 61.0
  • Book Value ₹ 115
  • Dividend Yield 1.27 %
  • ROCE 66.2 %
  • ROE 49.0 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 36.8%
  • Company has been maintaining a healthy dividend payout of 109%

Cons

  • Stock is trading at 28.7 times its book value
  • The company has delivered a poor sales growth of 2.92% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 Nifty 500 BSE MidCap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
792 729 906 799 782 738 953 805 911 811 1,000 946 966
618 582 649 571 615 597 667 587 656 582 681 656 635
Operating Profit 173 148 257 228 167 141 287 218 255 229 319 290 331
OPM % 22% 20% 28% 29% 21% 19% 30% 27% 28% 28% 32% 31% 34%
1,322 31 22 12 38 54 28 -135 32 36 37 35 39
Interest 0 1 0 0 1 0 0 0 1 0 0 0 1
Depreciation 15 16 16 16 17 16 18 17 18 16 17 19 15
Profit before tax 1,480 162 262 224 187 179 297 65 269 248 339 306 355
Tax % 18% 27% 26% 27% 30% 27% 27% 30% 28% 27% 27% 25% 27%
1,218 119 194 164 131 131 216 45 193 182 249 229 260
EPS in Rs 71.89 7.01 11.43 9.68 7.76 7.71 12.72 2.69 11.40 10.72 14.68 13.49 15.36
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Dec 2013 Mar 2015 15m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
2,546 3,288 2,826 2,903 2,872 3,129 3,225 2,920 3,218 3,216 3,407 3,723
2,024 2,660 2,349 2,482 2,361 2,522 2,566 2,323 2,462 2,417 2,507 2,554
Operating Profit 522 627 477 421 511 606 658 598 756 799 901 1,169
OPM % 20% 19% 17% 14% 18% 19% 20% 20% 23% 25% 26% 31%
227 147 125 118 69 106 -247 8 1,402 104 -20 147
Interest 0 0 0 0 0 1 6 4 2 2 2 1
Depreciation 20 25 25 27 38 49 83 79 68 66 70 67
Profit before tax 729 749 576 511 542 664 322 524 2,087 835 809 1,248
Tax % 31% 37% 35% 34% 35% 36% 66% 32% 19% 27% 28% 26%
502 472 375 337 352 425 110 358 1,691 608 585 919
EPS in Rs 29.63 27.84 22.11 19.88 20.78 25.11 6.50 21.11 99.79 35.88 34.51 54.25
Dividend Payout % 84% 112% 113% 75% 84% 80% 616% 142% 90% 89% 93% 144%
Compounded Sales Growth
10 Years: 1%
5 Years: 3%
3 Years: 5%
TTM: 9%
Compounded Profit Growth
10 Years: 6%
5 Years: 36%
3 Years: -18%
TTM: 41%
Stock Price CAGR
10 Years: 8%
5 Years: 19%
3 Years: 30%
1 Year: 26%
Return on Equity
10 Years: 30%
5 Years: 45%
3 Years: 37%
Last Year: 49%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 85 85 85 85 85 169 169 169 169 169 169 169
Reserves 1,932 1,767 2,120 1,944 1,995 1,973 1,671 1,328 2,508 1,584 1,615 1,780
4 3 2 2 1 1 0 35 20 16 19 10
1,129 1,382 864 991 1,884 1,766 1,291 1,565 1,925 1,559 1,745 2,142
Total Liabilities 3,150 3,236 3,071 3,021 3,965 3,909 3,132 3,097 4,623 3,328 3,548 4,101
100 123 204 258 325 432 758 387 331 330 321 284
CWIP 62 115 268 605 923 1,003 120 13 30 20 14 14
Investments 58 48 54 48 48 25 24 24 390 543 838 1,143
2,930 2,950 2,545 2,110 2,670 2,450 2,229 2,672 3,871 2,435 2,375 2,660
Total Assets 3,150 3,236 3,071 3,021 3,965 3,909 3,132 3,097 4,623 3,328 3,548 4,101

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
267 341 138 232 475 411 491 595 820 488 579 1,280
198 178 499 303 -107 -154 -63 408 -420 805 15 -37
-490 -497 -638 -511 -307 -358 -428 -696 -524 -1,544 -562 -769
Net Cash Flow -25 22 -1 25 61 -102 0 307 -124 -251 32 474

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Dec 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 14 11 16 21 19 14 11 27 23 22 24 29
Inventory Days 108 89 155 111 147 131 135 153 144 128 146 124
Days Payable 88 74 96 72 148 109 99 131 156 122 174 188
Cash Conversion Cycle 34 26 75 61 18 37 47 49 11 27 -4 -36
Working Capital Days -46 -49 25 6 -91 -72 -35 -36 -95 -58 -65 9
ROCE % 35% 41% 28% 22% 26% 31% 33% 37% 36% 36% 51% 66%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00% 75.00%
2.16% 2.17% 2.28% 2.28% 2.41% 2.50% 2.93% 3.48% 4.02% 4.36% 4.50% 4.52%
10.65% 10.54% 10.29% 10.31% 10.25% 10.01% 8.64% 7.90% 7.51% 7.34% 7.30% 7.79%
0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
12.19% 12.29% 12.43% 12.43% 12.35% 12.48% 13.42% 13.62% 13.48% 13.30% 13.21% 12.69%
No. of Shareholders 1,12,9641,16,6511,20,1271,20,4151,19,0321,15,2681,14,6631,18,9941,18,5151,19,2281,19,6251,21,885

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls